Pharmacological activation of the Nrf2 pathway by 3H-1, 2-dithiole-3-thione is neuroprotective in a mouse model of Alzheimer disease
Beyond weight loss, many patients experience other metabolic improvements, such as better blood pressure, improved cholesterol levels, and a reduced risk of developing type 2 diabetes
The protocol continues with 1 mg weekly (weeks 912), followed by 1.7 mg weekly (weeks 1316), and finally the maintenance target of 2.4 mg weekly
The even more convenient weekly injection becomes known, like all other GLP-1 drugs, for its weight loss side effects
Most current GLP-1 users are interested in switching to a pill, and many have already taken steps to do so